Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002
November 19, 2020 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to...
Bio-Path Holdings Reports Third Quarter 2020 Financial Results
November 13, 2020 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to...
Bio-Path Holdings to Announce Third Quarter 2020 Financial Results on November 13, 2020
November 06, 2020 08:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Receives Notice of Allowance for Strategic Patent for Prexigebersen in Combination with Front Line Cytidine Analogues or Bcr-Abl Tyrosine Kinase Inhibitors in a Variety of Cancers
October 22, 2020 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
Bio-Path Holdings to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 09, 2020 08:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to...
Bio-Path Holdings Reports Second Quarter 2020 Financial Results
August 14, 2020 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to...
Bio-Path Holdings Announces First Patient Dosed in Amended Stage 2 of the Phase 2 Clinical Trial Evaluating Prexigebersen in Acute Myeloid Leukemia
August 13, 2020 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings to Announce Second Quarter 2020 Financial Results on August 14, 2020
August 07, 2020 08:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Presents at 2020 American Society of Clinical Oncology Annual Meeting
May 29, 2020 08:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, May 29, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Reports First Quarter 2020 Financial Results
May 15, 2020 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, May 15, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop...